その他の免疫調節薬

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
 Cavalli G, et al.〔Lancet Respir Med. 2021 Mar 4:S2213-2600(21)00099-0〕（査読済み）


IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study
 Franzetti M, et al.〔J Immunol. 2021 Apr 1;206(7):1569-1575〕（査読済み）


Efficacy of early anti-inflammatory treatment with high doses IV Anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
 Pontali E, et al.〔J Allergy Clin Immunol. 2021 Apr;147(4):1217-1225〕（査読済み）